Pharming Group to participate in November investor conferences

Leiden, The Netherlands, November 1, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of November:

• Stifel 2023 Healthcare Conference, New York, November 14-15Anurag Relan, Chief Medical Officer will participate in a fireside chat, question and answer session on Tuesday, November 14 at 08:35 am ET/14:35 CET.
• Jefferies London Healthcare Conference 2023, London, U.K., November 14-16Sijmen de Vries, Chief Executive Officer will present on Wednesday, November 15 at 08:30 GMT/09:30 CET.

For more information about these conferences, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at [e-mail] or your Stifel or Jefferies representative.

About Pharming Group N.V.

Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:

Pharming Group, Leiden, The NetherlandsMichael Levitan, VP Investor Relations & Corporate CommunicationsT: [phone]

Heather Robertson, Investor Relations & Corporate Communications ManagerE: [e-mail]

FTI Consulting, London, UK

Victoria Foster Mitchell/Alex Shaw/Amy ByrneT: [phone]

LifeSpring Life Sciences Communication, Amsterdam, The NetherlandsLeon MelensT: [phone]E: [e-mail]